Table 1.
Baseline characteristics by radiographic progression at 1 year and bone mineral density loss after 3 months
| Total | Radiographic progression | BMD loss | |||||
|---|---|---|---|---|---|---|---|
| No | Yes | p value | No | Yes | p value | ||
| Age | 58 (14.5) | 57.9 (14.4) | 60.3 (14.7) | 0.41 | 55.7 (15.5) | 60.3 (13.4) | 0.042 |
| Women, n (%) | 107 (64) | 84/135 (62.2) | 23/32 (71.9) | 0.41 | 38/69 (55.1) | 69/98 (70.4) | 0.05 |
| Symptom duration (months) | 6 (3.7) | 5.5 (3.3) | 6.4 (5.0) | 0.35 | 6 (3.2) | 5.5 (3.9) | 0.31 |
| Anti-CCP2 positive, n (%) | 107 (64) | 88/135 (65.2) | 19/32 (59.4) | 0.54 | 42/69 (60.8) | 65/98 (66.3) | 0.51 |
| RF positive, n (%) | 103 (63) | 83/131 (63.4) | 20/32 (62.5) | 1.0 | 40/68 (58.8) | 63/95 (66.3) | 0.41 |
| ESR (mm/h) | 29 (21.4) | 27.3 (21.1) | 35.4 (21.8) | 0.055 | 25.4 (18.2) | 31.3 (23.2) | 0.066 |
| CRP (mg/ml) | 22 (24.4) | 21.6 (25.0) | 24.7 (22.2) | 0.51 | 18.2 (23) | 25 (25.1) | 0.074 |
| DAS 28 | 4.86 (1.30) | 4.79 (1.3) | 5.12 (1.4) | 0.21 | 4.57 (1.27) | 5.06 (1.29) | 0.023 |
| HAQ | 0.94 (0.60) | 0.91 (0.59) | 1.08 (0.59) | 0.15 | 0.86 (0.55) | 1 (0.62) | 0.16 |
| Larsen total | 4.1 (4.9) | 3.57 (4.63) | 6.25 (5.46) | 0.005 | 3.16 ((4.23) | 4.73 (5.24) | 0.034 |
| DXR-BMD | 579.5 (86.1) | 584.7 (84.2) | 558.0 (91.7) | 0.115 | 600.6 (84.2) | 564.8 (84.7) | 0.008 |
| DXR-BMD loss | 0.68 (1.81) | −0.52 (1.65) | −1.37 (2.31) | 0.058 | 0.83 (1.05) | −1.74 (1.45) | < 0.001 |
Values are mean (SD) unless otherwise stated
Abbreviations: CCP cyclic citrullinated peptides, RF rheumatoid factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 Disease Activity Score, HAQ Health Assessment Questionnaire, DXR-BMD bone mineral density measured by digital X-ray radiogrammetry
p values in italics are statistically significant